Literature DB >> 24166746

Relationship of serum isoflavone, insulin and adiponectin levels with breast cancer risk.

Machiko Minatoya1, Goro Kutomi, Sumiyo Asakura, Seiko Otokozawa, Yukiko Sugiyama, Hirofumi Ohnishi, Hiroshi Akasaka, Tetsuji Miura, Mitsuru Mori, Koichi Hirata.   

Abstract

BACKGROUND: Obesity is one of the well-known risk factors of breast cancer. Accumulating evidence suggests that adiponectin, an obesity-related hormone, is inversely associated with breast cancer risk, particularly in postmenopausal women. Obesity is also associated with high levels of insulin. In addition, studies have suggested that the soy isoflavones present in the traditional Japanese diet have been associated with decreased risk of breast cancer. However, there is no study that has assessed associations between serum levels of isoflavones, insulin, adiponectin and the risk of breast cancer all together with menopausal status.
METHODS: In a case-control study of 63 histologically confirmed breast cancer patients and 76 controls, serum isoflavone, insulin, and high-molecular-weight (HMW) adiponectin levels and breast cancer risk were examined for their association with breast cancer risk after adjustment for various risk factors.
RESULTS: Women in the highest tertile of serum HMW adiponectin levels were associated with a statistically significant decreased risk for breast cancer compared with women in the lowest tertile [odds ratio (OR), 0.09; 95 % confidence interval (CI) 0.03-0.33]. This association was observed in postmenopausal women (OR 0.06; 95 % CI 0.01-0.28), but not in premenopausal women. The observed associations were independent of possible effects of insulin, body mass index, and known risk factors for breast cancer. Serum isoflavones and insulin levels were not associated with breast cancer risk.
CONCLUSIONS: This study suggests that high serum HMW adiponectin levels are significantly associated with a decreased risk for breast cancer. Our result support the hypothesis that serum adiponectin may act as a potential biomarker for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166746     DOI: 10.1007/s12282-013-0502-2

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  6 in total

1.  The Relationship between Adiponectin and Breast Cancer.

Authors:  Burcu Erbay; Tonguç Utku Yılmaz; Ceyla Eraldemir; Nihal Üren; Çağrı Tiryaki; Emel Ergül; Zafer Utkan
Journal:  J Breast Health       Date:  2016-04-01

2.  Favorable effects of low-fat and low-carbohydrate dietary patterns on serum leptin, but not adiponectin, among overweight and obese premenopausal women: a randomized trial.

Authors:  Adana Am Llanos; Jessica L Krok; Juan Peng; Michael L Pennell; Susan Olivo-Marston; Mara Z Vitolins; Cecilia R Degraffinreid; Electra D Paskett
Journal:  Springerplus       Date:  2014-04-04

Review 3.  Serum adiponectin in breast cancer: A meta-analysis.

Authors:  Li Gu; Chang Cao; Jing Fu; Qian Li; De-Hua Li; Ming-Yao Chen
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

4.  The association between adiponectin gene rs182052 polymorphism and cancer risk: a meta-analysis.

Authors:  Li-Fang Wu; Gui-Ping Xu; Qing Zhao; Ding Wang; Li-Jing Zhou; Bin Sun; Wei-Xian Chen
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

5.  Association of serum adiponectin with breast cancer: A meta-analysis of 27 case-control studies.

Authors:  Zeping Yu; Shenli Tang; Hongbing Ma; Hong Duan; Yong Zeng
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

6.  Association Between Serum Insulin and C-Peptide Levels and Breast Cancer: An Updated Systematic Review and Meta-Analysis.

Authors:  Manwen Li; Limin Song; Junhua Yuan; Di Zhang; Caishun Zhang; Yuan Liu; Qian Lin; Haidan Wang; Kaizhen Su; Yanrun Li; Zhengye Ma; Defeng Liu; Jing Dong
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.